iShares US Aerospace & Defense ETF vs Smith & Nephew plc — how do they compare? iShares US Aerospace & Defense ETF trades at $206.49 (market cap $11.87B), while Smith & Nephew plc trades at $27.14 (market cap $11.10B). The key difference: iShares US Aerospace & Defense ETF and Smith & Nephew plc are close in size by market cap, and Smith & Nephew plc pays a 2.95% dividend while iShares US Aerospace & Defense ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares US Aerospace & Defense ETF for 19 Days and Smith & Nephew plc for 120 Days on average.
| ITA | SNN | |
|---|---|---|
Market Cap | $11.87B | $11.10B |
Volume | 1,060,125 | 1,051,703 |
Sector | Sector/Thematic | Health |
52-Week High | $253.22 | $37.17 |
52-Week Low | $198.23 | $26.42 |
Typical Hold Time | 19 Days | 120 Days |
Enterprise Value | — | $14.13B |
Dividend Yield | — | 2.95% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SNN trades at $27.10, near its 52-week low, with a bearish technical signal. The company reported solid fundamentals with revenue growth to $6.16B in 2025 and a net income margin of 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. Cash flow from operations remains strong at $1.29B, though net cash flow was negative $64M in 2025.
The outlook is mixed: strong profitability and innovation support long-term value, but near-term headwinds include analyst downgrades and competitive pressures. Risks involve execution challenges and market sentiment. The stock presents a cautious opportunity for value investors, balancing solid fundamentals against current bearish trends.
Trailing returns across standard periods
iShares U.S. Aerospace & Defense ETF seeks to track U.S. companies in the aerospace and defense sector. Its holdings include manufacturers of commercial and military aircraft, defense systems, and related equipment.
Read more on ITA →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →